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Abstract
 
Recurrent herpes simplex virus type 1 (HSV-1) disease usually results from reactivation of la-
tent virus in sensory neurons and transmission to peripheral sites. Therefore, defining the
mechanisms that maintain HSV-1 in a latent state in sensory neurons may provide new ap-
proaches to reducing susceptibility to recurrent herpetic disease. After primary HSV-1 corneal
 
infection, CD8
 
1
 
 T cells infiltrate the trigeminal ganglia (TGs) of mice, and are retained in la-
tently infected ganglia. Here we demonstrate that CD8
 
1
 
 T cells that are present in the TGs at
the time of excision can maintain HSV-1 in a latent state in sensory neurons in ex vivo TG
cultures. Latently infected neurons expressed viral genome and some expressed HSV-1 imme-
diate early and early proteins, but did not produce HSV-1 late proteins or infectious virions.
 
Addition of anti-CD8
 
a
 
 monoclonal antibody 5 d after culture initiation induced HSV-1 reac-
tivation, as demonstrated by production of viral late proteins and infectious virions. Thus,
CD8
 
1
 
 T cells can prevent HSV-1 reactivation without destroying the infected neurons. We
propose that when the intrinsic capacity of neurons to inhibit HSV-1 reactivation from latency
is compromised, production of HSV-1 immediate early and early proteins might activate
CD8
 
1
 
 T cells aborting virion production.
Key words: cytotoxic T lymphocytes • trigeminal ganglion • mice • HSV-1 immediate early 
genes • HSV-1 late genes
 
Introduction
 
Primary HSV type 1 (HSV-1)
 
1
 
 infection in humans usually
occurs early in life, often without overt clinical manifesta-
tions. Recurrent herpetic disease results from reactivation
of HSV-1 from latency in sensory neurons and axonal
transport to the periphery. Animal studies revealed that
during primary infection the virus gains access to the ter-
mini of sensory neurons, and is transported by retrograde
axonal transport to the sensory ganglia (1). There, the virus
replicates briefly and then establishes a latent infection.
Studies in mice suggest that acute virus replication in the
sensory ganglia after primary infection is controlled by an
initial innate immune response followed by an adaptive im-
mune response in which CD8
 
1
 
 T lymphocytes play an im-
portant role (2–5).
The effectiveness of the immune response to primary
HSV-1 infection may determine the number of neurons
that harbor latent virus, and the number of copies of viral
genome within each latently infected neuron. Both of
these factors appear to be important in determining the
likelihood of a reactivation event (6–9). The observation
that lymphocytes and their cytokine products persist in la-
tently infected trigeminal ganglia (TGs) suggests a possible
continuing role for the immune system in controlling
HSV-1 recurrences (3, 10–12). The immune system might
regulate HSV-1 reactivation from latency in sensory neu-
rons, and/or limit the transport of virus from sensory gan-
glia to the peripheral tissues they innervate.
HSV-1 does not appear to spontaneously reactivate from
latency in the sensory ganglia of mice in vivo. However,
the virus can reactivate from mouse ganglia in vitro, and
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can be induced to reactivate in vivo (13–17). Thus, the fac-
tors that maintain the viral genome in a latent state can be
overcome in vivo, and are generally not carried over to the
in vitro culture. This could reflect changes that are intrinsic
to the neurons, and/or a change in extrinsic factors such as
a loss of immune protection. A role for CD8
 
1
 
 T cells in
controlling HSV-1 replication in sensory ganglia is estab-
lished (5). We hypothesized that the capacity of HSV-1 to
reactivate from latency in explant cultures of mouse ganglia
might reflect the separation of the ganglion from HSV-spe-
cific CD8
 
1
 
 T cells in the peripheral blood. Two corollaries
to this hypothesis are: (a) the addition of exogenous CD8
 
1
 
T cells from immunized mice to ex vivo cultures of latently
infected ganglia could block HSV-1 reactivation from la-
tency; and (b) the requirement for exogenous CD8
 
1
 
 T
cells to protect a ganglion culture from HSV-1 reactivation
would depend on the density of CD8
 
1
 
 T cells in the gan-
glion at the time of excision.
Our previous studies (3) established that CD8
 
1
 
 T cells
begin to infiltrate the TG 5–7 d after HSV-1 corneal infec-
tion, concurrent with the elimination of replicating virus
from the ganglion. By 7 d after HSV-1 corneal infection,
few if any neurons in the TG expressed HSV-1 antigens.
However, CD8
 
1
 
 T cells continue to accumulate in the
ganglion and surround neurons in the ophthalmic branch
until 12–14 d after infection and remain in the ganglion in
diminishing numbers for at least 90 d. These studies tested
the capacity of CD8
 
1
 
 T cells to prevent HSV-1 reactiva-
tion from latency in cultures of TG that were excised 7, 14,
and 34 d after corneal infection.
 
Materials and Methods
 
HSV-1 Infection. 
 
6–8-wk-old female BALB/c mice (Freder-
ick Cancer Research Center) were anesthetized by intramuscular
injection of 2.0 mg of ketamine hydrochloride (Vetalar; Parke-
Davis) and 0.04 mg of acepromazine maleate (Aveco Co.) in 0.1
ml of HBSS. The RE strain of HSV-1 was grown in Vero cells,
and intact virions were purified on Percoll (Pharmacia LKB Bio-
technology, Inc.) as described (18). Corneas of anesthetized mice
were scarified 10 times in a crisscross fashion with a sterile 30-
gauge needle, and the eyes were infected topically with 3 
 
m
 
l of
PBS containing 10
 
5
 
 PFU of HSV-1.
 
Isolation of CD8
 
1
 
 T Cells from the LNs of Infected Mice. 
 
5 d af-
ter corneal infection, mice received an intraperitoneal injection
of 0.5 mg anti-CD4 (GK1.5) mAb. 2 d later, the draining preau-
ricular and submandibular LNs were excised, and single cell sus-
pensions were prepared and filtered through a 40-
 
m
 
m sterile filter
(Becton Dickinson Labware). The cell suspension was further en-
riched for CD8
 
1
 
 cells by a 1-h incubation on the plastic surface
of a flask, followed by three sequential passages on flasks coated
with anti-Ia mAbs (clone Ran-2, TIB 120; American Type Cul-
ture Collection). The nonadherent cells were incubated for 30
min with a biotinylated pan-NK mAb (1 
 
m
 
g/10
 
6
 
 cells, clone
DX5; PharMingen) and then exposed to a combination of mag-
netic beads (six beads/targeted cell) coated with anti-CD4, anti-
B220 (pan–B cell), and streptavidin (Dynabeads; Dynal). After
exposure to the beads, three rounds of magnetic separation re-
moved the bound cells. The resulting cell suspensions were
 
$
 
98% CD8
 
1
 
 cells.
 
Preparation of TG Cultures. 
 
At various times after HSV-1
corneal infection, the ipsilateral TG was excised and treated with
collagenase type I (Sigma Chemical Co.) 3 mg/ml for 1.5 h at
37
 
8
 
C and dispersed into single cells by trituration. The cells from
multiple TGs were pooled, and the neurons were counted. We
obtained an average yield of 17,200 
 
6 
 
7,600 neurons/ganglion,
which is similar to the yield reported previously (9). The equiva-
lent number of cells from one TG were added to each well of a
24-well tissue culture plate, and the cells were cultured with
DMEM and 10% FCS, and 10 U/ml recombinant murine IL-2
(R&D Systems, Inc.). Where indicated, cultures were treated
with 150 
 
m
 
g/ml anti-CD4 (GK1.5, IgG-2b, TIB 207; American
Type Culture Collection), anti-CD8 (2.43, IgG-2b, TIB 210;
American Type Culture Collection), or control antibody anti–
HLA-BW6 (SFR8-B6, IgG-2b, HB-152; American Type Cul-
ture Collection).
 
Reverse Transcription PCR. 
 
At various times after initiation of
TG cultures, the cells were scraped off the surface of the well and
total RNA was extracted from the cells using RNeasy™ total
RNA kits (Qiagen). The RNA was treated with 1 U/
 
m
 
g amplifi-
cation grade DNase I (GIBCO BRL), followed by repurification
with RNeasy™ clean-up protocol (Qiagen). First strand cDNA
was prepared from a portion of each RNA sample using the re-
verse transcription (RT) system (Promega). The cDNA encoding
HSV-1 glycoprotein C (gC) was expanded through 35 cycles of
PCR using the primer sets: sense 5
 
9
 
-GCC AGA TCG ACA
CGC AGA CG-3
 
9
 
, and antisense 5
 
9
 
-CGA AAT GGG CAG
GGT GGA CC-3
 
9
 
. As a standard, cDNA encoding the house-
keeping gene hypoxanthineguanine phosphoribosyl transferase
(HPRT) was expanded through 26 PCR cycles using the primer
sets: sense, 5
 
9
 
-CTC GAA GTG TTG GAT ACA GGC-3
 
9
 
, and
antisense 5
 
9
 
-GAT AAG CGA CAA TCT ACC AGA G-3
 
9
 
. To
detect amplification of genomic DNA contaminating our RNA
preparation, 35 cycles of PCR was performed with gC-specific
primers on a portion of the original RNA (omitting RT).
 
Detection of HSV-1 Genomic DNA and Protein in Neurons.
 
Cultures were simultaneously stained by immunofluorescence for
HSV proteins, and by fluorescence in situ hybridization (FISH)
for HSV genome using a modification of a protocol that was de-
scribed previously (19). The TG cultures were fixed with Histo-
CHOICE tissue fixative MB (Amresco) for 30 min at room tem-
perature, and rinsed with 1
 
3
 
 PBS with 0.1% saponin. For
immunofluorescent staining, the cultures were treated with 3%
H
 
2
 
O
 
2
 
 for 10 min at RT, rinsed with PBS-saponin, and blocked
with blocking buffer (5% normal goat serum in 1
 
3
 
 PBS-sapo-
nin). Cultures were then incubated overnight at 4
 
8
 
C with rabbit
polyclonal antibody specific for HSV-1 (Accurate Chemical &
Scientific Corp.), for HSV-1 infected cell protein (ICP)4, for
HSV-1 ICP8, or for HSV-1 gC. After rinsing with PBS-saponin,
the cultures were incubated for 1 h at room temperature with
Cy3-conjugated sheep F(ab
 
9
 
)
 
2
 
 anti–rabbit IgG (Sigma Chemical
Co.) and rinsed with PBS-saponin. For FISH, the cultures were
dehydrated with 100% ETOH and rinsed twice with 2
 
3
 
 SSC,
followed by addition of a cocktail of four digoxigenin-dUTP–
conjugated HSV-specific probes representing the entire HSV ge-
nome (20). The cultures were covered with a coverslip, and the
probes were denatured for 5 min at 80
 
8
 
C, hybridized 1–3 h at
45
 
8
 
C, washed three times for 5 min with 2
 
3
 
 SSC and 50% for-
mamide at 45
 
8
 
C, washed three times for 5 min with 0.1
 
3
 
 SSC at
60
 
8
 
C, and washed three times for 5 min in TNT (Tris-HCl,
NaCl, pH 7.4, Tween 20) at room temperature. The cells were
blocked for 30 min at room temperature with blocking reagent
(TSA™-Direct [GREEN]; NEN
 
®
 
 Life Science Products, Inc.), 
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incubated for 30 min at room temperature with sheep antidigox-
igenin-POD (Fab fragments; Boehringer Mannheim), washed
with TNT, developed for 5 min with FITC-tyramide (TSA™-
Direct [GREEN]; NEN
 
®
 
 Life Science Products, Inc.), washed
with TNT, and then washed with distilled water to remove the
salts. The cultures were mounted with Gelvatol (polyvinyl alco-
hol and glycerol) and examined by confocal microscopy. The
combination of four probes spanning the entire viral genome and
enhanced fluorescence detection resulted in highly sensitive de-
tection of viral DNA. The probes did not bind mouse DNA, as
no staining of TG neurons from noninfected mice was detectable
by this procedure (not shown).
 
HSV-1 Titration in Culture Supernatant Fluids. 
 
At various times
after culture initiation, 150 
 
m
 
l of medium was removed from
each culture, and the number of released infectious virions was
determined in a standard virus plaque assay on monolayers of
Vero cells (21). After each sampling, the medium was replaced
with an equal volume of fresh medium of the same composition.
 
Results
 
TG Cultures. 
 
The ipsilateral TGs were excised from
mice 7, 14, or 34 d after HSV-1 corneal infection. A gan-
glion is considered to harbor latent HSV-1 if a homoge-
nate of freshly excised ganglion lacks detectable infectious
virus when added to a monolayer of susceptible cells, but
pieces of the ganglion produce infectious virus when cul-
tured on a monolayer of susceptible cells. Homogenates of
TGs obtained 7 d after HSV-1 corneal infection showed
variable presence of infectious HSV-1 when added to a
monolayer of Vero cells, whereas homogenates of TG ob-
tained 14 or 34 d after HSV-1 corneal infection did not
contain infectious virus. These findings demonstrated that
at 7 d after infection, some of the TGs still contained repli-
cating virus, whereas in some day 7 TGs, and in all day 14
TGs and day 34 TG, HSV-1 had apparently already uni-
formly established a latent infection in all infected neurons.
TGs were dispersed into single cell suspensions and cul-
tured in 24-well tissue culture plates. Within 3 d of initia-
tion of all TG cultures, multiple neurons were observed
resting on a monolayer of fibroblasts. The purpose of these
cultures was to determine if CD8
 
1
 
 T cells could maintain
HSV-1 in a latent state in TG neurons. Latency was demon-
strated and distinguished from slow virus replication on the
basis of the following criteria: (a) no infectious virus in sam-
ples of culture supernatants, (b) detectable viral genome in
some neurons, (c) no viral cytopathic effect in fibroblasts
surrounding neurons, (d) no viral late gene products detect-
able by immunofluorescence staining, and (e) no mRNA
for the viral late gene gC detectable by RT-PCR. As op-
posed to destroying neurons harboring the virus, mainte-
nance of HSV-1 in a latent state was established by demon-
strating the appearance of viral late gene products and
infectious virus after addition of anti-CD8
 
a
 
 mAb to cultures
that harbored latent HSV-1 as defined by the above criteria.
 
CD8
 
1
 
 T Cells That Are Present in TGs 7 d after HSV-1
Corneal Infection Can Inhibit HSV-1 Replication Ex Vivo.
 
All day 7 TG cultures produced infectious viral particles
that were detectable in the culture supernatant fluids by 48 h
 
of incubation (Fig. 1). Viral titers increased until 4–6 d,
when all cells in the cultures were destroyed and viral titers
declined. A similar pattern of HSV-1 production was ob-
served in cultures that were treated with anti-CD4 mAb or
control mAb. Cultures treated with anti-CD8
 
a
 
 mAb pro-
duced significantly more virus (
 
P
 
 
 
, 
 
0.05, days 4–8) than
those grown in culture medium containing control mAb or
anti-CD4 mAb (Fig. 1). Virus production was similar in
cultures treated with anti-CD8
 
a
 
 alone and those treated
with a combination of anti-CD4 plus anti-CD8 mAb.
Moreover, the addition of exogenous purified CD8
 
1
 
 T
cells obtained from HSV-1–immunized mice completely
blocked the production of infectious HSV-1 in day 7 TG
cultures (Fig. 1). The CD8
 
1
 
 T cells from nonimmune mice
had no effect (not shown). Thus, the CD8
 
1
 
 T cells that
were present in the TG 7 d after HSV-1 corneal infection
could inhibit but not completely abrogate HSV-1 replica-
tion in TG cells. The requirement for exogenous CD8
 
1
 
 T
cells to fully establish a latent infection in day 7 TG cultures
is consistent with the observation that CD8
 
1
 
 T cells accu-
mulate in the TG from day 7 to day 14 after corneal infec-
tion in concert with the establishment of latency.
 
CD8
 
1
 
 T Cells Present in TGs 14 d after HSV-1 Corneal
Infection Can Block HSV-1 Reactivation from Latency. 
 
Ho-
mogenates of TGs that were obtained 
 
$
 
14 d after HSV-1
corneal infection were devoid of replicating virus, demon-
strating that HSV-1 latency was uniformly established by
that time. As CD8
 
1
 
 T cells were at maximal density in the
TGs by 14 d after infection, we expected that cultures of
these TGs would be less dependent on exogenous CD8
 
1
 
 T
cells for protection from HSV-1 reactivation. In fact,
Figure 1. HSV-1 replication in day 7 TG cultures. TGs were excised 7 d
after HSV-1 corneal infection, and single cell suspensions were prepared
and pooled. Cultures (1 TG equivalent of TG cells) were incubated with
300 mg/ml of control mAb (s), 150 mg/ml of rat anti–mouse CD4 mAb
(,), 150 mg/ml of rat anti–mouse CD8a mAb (e), 150 mg each of anti-
CD4 and anti-CD8 mAbs (d), or exogenous CD81 T cells obtained
from the LNs of Balb/c mice 7 d after HSV-1 corneal infection (h). On
alternate days, 150 ml of culture supernatant fluid was removed from each
culture and replaced by fresh medium of the same composition. The su-
pernatant fluids were assayed for infectious HSV-1 with a standard virus
plaque assay. Pooled data from three assays (n 5 10) are presented as the
mean PFU/TG 6 SEM. 
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late HSV-1 proteins, were expressed in protected cultures.
In day 14 TG cultures that were incubated for 8 d with a
control mAb, the IE protein ICP4 (Fig. 3 f) and the early
protein ICP8 (Fig. 3 j) were detectable in the nuclei of
some neurons that contained viral genome. ICP4 was con-
sistently detected in cultures treated with control mAb in
 
z
 
1% of HSV-1 genome
 
1
 
 neurons. ICP8 expression was
not consistently observed in cultures treated with control
mAb, and in positive cultures was only detected in one to
two neurons. The amount of viral genome detected by
FISH varied greatly in different latently infected neurons
within each culture (as illustrated in Fig. 3, b, f, j, and n).
There appears to be a positive correlation between HSV-1
genome copy number and susceptibility to reactivation in
latently infected neurons (22). HSV-1 IE and early proteins
appeared to be preferentially expressed in latently infected
neurons containing relatively large amounts of HSV-1 ge-
nome as detected by FISH (Fig. 3, f and j). None of the
neurons in cultures that were incubated with control mAb
expressed detectable levels of the HSV-1 late gene product
gC (Fig. 3 n). Moreover, gC transcripts were not detect-
able by RT-PCR in RNA obtained from most day 14 TG
cultures that were incubated for 8 d with control mAb
(Fig. 4). The significance of the weak gC bands in some
protected cultures is uncertain due to the presence of con-
taminating genomic DNA.
When day 14 TG cultures were incubated for 5 d with
medium followed by 3 d with anti-CD8
 
a
 
 mAb, ICP4
(Fig. 3 h), ICP8 (Fig. 3 l), and gC (Fig. 3 p) were readily
detectable. The IE and early proteins were restricted to the
nucleus before and after reactivation (Fig. 3, f, h, j, and l),
whereas gC was detectable in the nucleus and in the cyto-
plasm after reactivation (Fig. 3 p).
 
CD8
 
1
 
 T Cells Present in TGs 34 d after HSV-1 Corneal
Infection Can Delay, but Not Completely Block HSV-1 Reacti-
vation from Latency.
 
 
 
All cultures of TGs that were ob-
tained 34 d after HSV-1 corneal infection produced infec-
tious virus within 5 d of culture initiation (Fig. 5). The
average HSV-1 titer in day 34 TG cultures was increased
 
z
 
10-fold (P , 0.05) by the addition of anti-CD8a mAb
on days 3–7 of culture (A), and reactivation was signifi-
cantly (P 5 0.0061, survival analysis) accelerated in these
cultures compared with cultures treated with control mAb
(Fig. 5 B). Thus, the CD81 T cells that remained in the
TGs 34 d after infection could delay HSV-1 reactivation
from latency and/or reduce HSV-1 production after reac-
tivation. The addition of CD81 T cells from immunized
mice to day 34 TG cultures completely blocked HSV-1 re-
activation, and this protection was eliminated when anti-
CD8a mAb was added 5 d after culture initiation (Fig. 5,
A and B).
The CD81 T cell–supplemented day 34 TG cultures
were analyzed for neuronal expression of HSV-1 DNA,
the HSV-1 IE protein ICP4, the early protein ICP8, and
the late protein gC as described previously for day 14 TG
cultures. The results were identical to those depicted in
Fig. 3. A small percentage (z1%) of neurons in day 34 TG
cultures consistently coexpressed HSV-1 DNA and ICP4,
Figure 2. CD81 T cells present in the TG 14 d after infection can block
HSV-1 reactivation from latency. TGs were excised 14 d after HSV-1 cor-
neal infection, and single cell suspensions were prepared and pooled. Cul-
tures (1 TG equivalent) were incubated in culture medium containing 150
mg/ml of control mAb (m), 150 mg/ml of anti-CD8a mAb (d); or cul-
tures were incubated for 5 d in culture medium, followed by 4 d of incu-
bation in medium containing 150 mg of anti-CD8a mAb (n). Samples of
culture supernatant fluids were assayed for infectious HSV-1 titers and
scored as positive (reactivation) or negative. Pooled data from three assays
(n 5 15) are presented as the percentage of cultures that reactivated.
HSV-1 reactivation from latency was blocked in day 14
TG cultures without the addition of exogenous CD81 T
cells (Fig. 2). The failure of HSV-1 to reactivate from la-
tency in these cultures was clearly due to a protective effect
of endogenous CD81 T cells, as reactivation promptly oc-
curred after the addition of anti-CD8a mAb to the TG
cultures.
Do CD81 T Cells Prevent HSV-1 Reactivation by Destroy-
ing Latently Infected Neurons?  An important observation
in these studies was that CD81 T cells could prevent HSV-1
reactivation from latency in TG cultures without elimi-
nating the reservoir of latently infected neurons. This was
established in several ways. First, the addition of anti-
CD8a mAb to day 14 TG cultures after 5 d of incubation
(when culture fluids lacked detectable virus) resulted in
production of infectious virus within 24 h (Fig. 2). Second,
day 14 TG cultures that were incubated for 8 d with con-
trol mAb lacked HSV-1 proteins that were detectable by
immunofluorescent staining with a polyclonal anti-HSV
antibody, although a mean of 33.5 6 1.76% of the neurons
in these cultures expressed HSV-1 genome as detected by
FISH (Fig. 3 b). However, when anti-CD8a mAb was
added to day 14 TG cultures after 5 d of incubation, neu-
rons that expressed both HSV-1 genome and HSV-1 pro-
teins were detectable within 3 d (Fig. 3 d). The viral pro-
teins were initially restricted to neurons, but later spread to
surrounding fibroblasts. Focal areas of viral cytopathic ef-
fect were observed by 72 h after anti-CD8a mAb treat-
ment, often progressing to complete destruction of the cul-
tures by 5 d after treatment (not shown).
The viral proteins recognized by the polyclonal antise-
rum used in these studies are undefined, but are likely to be
primarily viral late gene products that are expressed on cells
in conjunction with virus replication. We next determined
if HSV-1 immediate early (IE) and early proteins, but not1463 Liu et al.
whereas ICP8 expression was sporadic. No gC was detect-
able in CD81 T cell–supplemented cultures, but gC was
readily detectable 3 d after the addition of anti-CD8a mAb
to these cultures.
Discussion
Our studies clearly establish that the CD81 T cells that
infiltrate the TGs after HSV-1 corneal infection are capable
of inhibiting HSV-1 replication. This is not a particularly
surprising finding, although to our knowledge it has not
been previously demonstrated. The startling observation
that emerged from these studies was that the CD81 T cells
that infiltrated the TG after corneal infection can prevent
HSV-1 reactivation from latency in sensory neurons for .9 d
in ex vivo cultures. This observation is startling because it
challenges the prevalent notion that the immune system
responds to reactivation events, whereas maintenance of
HSV-1 latency is an intrinsic property of neurons. This no-
tion is based on the concept that the virus is invisible to the
immune system during latency because (a) no virus proteins
are produced in latently infected neurons, and (b) neurons
do not express MHC molecules that are required for T cell
Figure 4. CD81 T cells present in the TG 14 d after HSV-1 corneal
infection prevent the expression of mRNA for the HSV-1 late gene gC.
TGs were excised 14 d after HSV-1 corneal infection, and single cell sus-
pensions were prepared and pooled. 13 cultures were prepared (1 TG
equivalent/culture) and incubated for 5 d in culture medium. The cells
were removed from five cultures, and RNA was extracted. The remain-
ing cultures were incubated for an additional 3 d with control mAb or
with anti-CD8a mAb. RNA was extracted from these cultures on day 8.
All RNA preparations were treated with DNase. A portion of the RNA
from each culture was reverse transcribed (RT1), and HSV gC cDNA
was amplified through 35 cycles of PCR, or HPRT cDNA was ampli-
fied through 26 cycles of PCR as described in Materials and Methods.
To control for contaminating genomic DNA, PCR was performed on a
portion of the RNA from each culture without RT (RT2). HSV-1 ge-
nomic DNA contamination was heaviest in cultures treated with anti-
CD8a mAb, probably due to virus replication in these cultures.
Figure 3. The CD81 T cells
present in the TG 14 d after
HSV-1 corneal infection can
control viral gene expression in
latently infected neurons. TGs
were excised 14 d after HSV-1
corneal infection, and single cell
suspensions were prepared and
pooled. Cultures (1 TG equiva-
lent) were incubated for 5 d in
culture medium followed by 3 d
incubation with control mAb
(first two pictures in each row)
or anti-CD8a mAb (last two
pictures in each row). The cul-
tures were then stained simulta-
neously for HSV-1 genome by
FISH (green), and by immuno-
fluorescence (red) with a polyspe-
cific anti–HSV-1 antibody (b
and d), or with monospecific an-
tibody to the HSV-1 IE protein
ICP4 (f and h), the HSV-1 early
protein ICP8 (j and l), or the
HSV-1 late protein gC (n and p).
The cultures were examined by
confocal microscopy and repre-
sentative fields are depicted in
phase–contrast and fluorescence
in sequential photomicrographs
(i.e., a and b, c and d, etc.). Areas
that were positive for both viral
genome and viral protein appear
yellow. Neurons from TGs of
noninfected mice did not stain
by either the FISH or the immu-
nofluorescence techniques (not
shown). Bar (p), 10 mm.1464 CD81 T Cells Control HSV-1 Reactivation from Latency
receptor recognition of antigenic peptides. Both of these
concepts are challenged by our current findings and those
recently reported by other groups.
Cultures of TGs that were obtained 14 d after HSV-1
corneal infection contained numerous neurons that ex-
pressed detectable viral genome, but did not express viral
proteins that were detectable with a polyclonal anti-HSV
antiserum, or infectious viral particles. The virus remained
latent for up to 2 wk in 33.5% of neurons in these TG cul-
tures as defined by the detection of viral DNA (by FISH),
but the absence of viral late gene products, viral cytopathic
effect, or infectious virus. This finding is in agreement with
that of Sawtell (9), that 30.5% of TG neurons harbor latent
virus after HSV-1 corneal infection with a similar infec-
tious dose.
HSV-1 entry into the replicative cycle ensued within 24 h
of addition of anti-CD8a mAb to day 14 TG cultures.
The rapid activation of viral genes after addition of anti-
CD8a mAb to cultures suggested constant surveillance by
CD81 T cells. This raised several intriguing questions.
How was CD81 T cell activation maintained in cultures
that appeared to lack viral proteins? If the CD8 coreceptor
functions by augmenting TCR signaling, what is the TCR
ligand in these cultures? The polyclonal anti-HSV antise-
rum that was used in our initial studies to identify HSV
proteins was probably directed primarily against late viral
proteins that are expressed during virus replication on the
surface of infected cells. Such an antiserum might not de-
tect HSV-1 IE and early proteins that can be expressed in
the absence of viral DNA replication.
It is widely believed that HSV-1 proteins are not pro-
duced in latently infected neurons. However, recent studies
demonstrated the presence of low levels of transcripts for
the HSV-1 IE gene ICP4 and early gene for thymidine ki-
nase in latently infected ganglia (23, 24). Using immuno-
fluorescence staining, we established that 5 and 8 d after
culture initiation the HSV-1 IE protein ICP4, and to a
lesser extent the HSV-1 early protein ICP8, were present
in a small number of neurons that harbored viral genome
and that failed to produce the late viral protein gC. We
cannot formally rule out the possibility that the ICP4 de-
tected in these neurons was carried over from a transient
productive infection that may have escaped detection early
in the culture period. However, we consider this very un-
likely because ICP4 is produced more transiently and in
smaller quantities than gC during productive infection. In-
deed, during acute HSV-1 infection of the TG we rou-
tinely observe multiple neurons in histologic sections that
express readily detectable gC but no ICP4. In contrast, we
have never observed ICP41 neurons that lacked gC (our
unpublished observations). Thus, we believe that our find-
ings and those of Coen and colleagues (23) favor the view
that ICP4 and some early viral proteins are produced at low
levels and perhaps transiently in latently infected neurons.
After addition of anti-CD8a mAb to the cultures, ex-
pression of HSV-1 IE and early proteins increased, and gC
expression was readily detectable in both the cytoplasm and
nuclei of HSV genome1 neurons. Thus, CD81 T cells can
directly or indirectly regulate viral gene expression. We hy-
pothesize that low level, and perhaps intermittent produc-
tion of IE and early proteins by latently infected neurons in
TG cultures might have provided the necessary signal to
maintain CD81 T cells in an activated state in which they
are capable of preventing the virus from progressing
through its life cycle. MHC class I proteins are reportedly
expressed on sensory neurons for at least 2 wk after HSV-1
infection, but are not detectable in sensory ganglia obtained
64 wk after infection (25). We propose that early in the
process of HSV-1 reactivation, latently infected neurons
begin to produce both HSV-1 IE and early proteins and
MHC class I. The concomitant expression of HSV-1 pro-
teins and MHC class I might activate HSV-1–specific
Figure 5. CD81 T cells remaining in the TG 34 d after HSV-1 corneal infection can delay HSV-1 reactivation but require supplementation to block
reactivation. TGs were excised 34 d after HSV-1 corneal infection, and single cell suspensions were prepared and pooled. Cultures (1 TG equivalent) were
incubated in medium containing 150 mg/ml of control mAb (d), or 150 mg/ml of rat anti–mouse CD8a mAb (s). Other cultures received exogenous,
highly enriched CD81 T cells from HSV-1–immunized mice and were incubated in medium alone from day 1 to day 5, followed by control mAb (m) or
anti-CD8a mAb (n) from day 5 to day 10. Samples of culture supernatant fluids were assayed for infectious HSV-1 titers and scored as positive (reactiva-
tion) or negative. Pooled data from two assays (n 5 16) are presented as the PFU/culture (A) or percentage of cultures in which HSV-1 reactivated (B).1465 Liu et al.
CD81 T cells. The low epitope density on the neurons
might favor CTL production of antiviral cytokines without
activation of the lytic machinery, thus reversing the HSV
reactivation process while sparing the neuron.
Our previous study established that HSV-1 proteins are
no longer detectable on TG neurons 7–10 d after corneal
infection, as assessed by immunofluorescence staining with
a polyclonal anti-HSV antiserum (3). However, CD81 T
cells continued to accumulate in the TG and surround
neurons until 12–14 d after infection. Based on our current
findings, we propose that the continued infiltration and re-
tention of CD81 T cells in the ganglion might be in re-
sponse to the production of HSV-1 IE and early proteins.
We also observed that the number of CD81 T cells in the
ganglion declined threefold 12–30 d after infection (3).
The reason for the decline in the number of CD81 T cells
in the ganglion after day 12–14 after infection is not clear.
One possibility would be that viral IE and early gene ex-
pression gradually declines after the onset of latency. How-
ever, there was no apparent reduction of ICP4 or ICP8
production by latently infected neurons in day 34 TG cul-
tures compared with day 14 TG cultures.
We favor the hypothesis that CD81 T cell infiltration of
the TG 14 d after infection is influenced by both a reaction
to low-level HSV-1 protein production by latently infected
neurons, and an inflammatory environment established in
the ganglion during the period of virus replication. The
fact that some CD81 T cells remain in the TG .30 d after
infection may reflect continued low-level production of
HSV-1 IE and early proteins by latently infected neurons.
The inability of these endogenous CD81 T cells to com-
pletely block HSV-1 reactivation in vitro probably reflects
their reduced numbers, as latency was maintained when
additional CD81 T cells were added to the cultures. More-
over, it is possible the CD81 T cells that are present in the
TG 34 d after infection are sufficient to maintain latency in
vivo. It is likely that more CD81 T cells are required to
prevent HSV-1 reactivation in ex vivo cultures due to a re-
duced intrinsic inhibitory capacity of the neurons, physical
separation of the neurons in culture, and dilution of soluble
factors produced by the CD81 T cells in culture fluid.
Although our data demonstrate that CD81 T cells that
infiltrate the infected TG are capable of blocking reactiva-
tion of HSV-1 in latently infected sensory neurons, it is un-
likely that this is the only mechanism for maintaining HSV-1
latency in vivo. We propose that under normal circumstances
factors intrinsic to the neurons can maintain the viral ge-
nome in a latent state. This is consistent with the observa-
tion that HSV-1 can establish latency in some sensory neu-
rons of mice with severe combined immune deficiency (26).
It appears, for instance, that signaling through nerve growth
factor can prevent HSV-1 reactivation from latency in sen-
sory neurons (27, 28). However, certain stimuli appear to
overcome the inhibitory environment within the neuron
and permit HSV-1 reactivation from latency. We believe
that CD81 T cells provide supplemental inhibition of HSV-1
reactivation at a time when the intrinsic inhibitory environ-
ment within sensory neurons is compromised.
It remains unclear why HSV-1 periodically reactivates
from latency in the sensory ganglia of humans, but does not
do so in mice. We propose that mouse CD81 T cells might
be more efficient than their human counterparts at block-
ing HSV-1 reactivation. The HSV ICP47 inhibits CD81 T
cell recognition of HSV-infected cells by blocking the
function of the transporters associated with antigen presen-
tation (29–31). Our studies demonstrated that this protein
significantly increased HSV-1 neurovirulence in mice (32).
However, ICP47 is much less effective at blocking trans-
porters associated with antigen presentation function in
mice than in humans (30, 33, 34). Thus, mouse CD81 T
cells might be more responsive to HSV-1 antigens than hu-
man CD81 T cells, particularly in situations where both vi-
ral protein and MHC class I antigen production are low.
The increased reactivity of mouse CD81 T cells to HSV-1
antigens on sensory neurons or surrounding cells might ac-
count for the inability of HSV to spontaneously reactivate
from latency in mouse sensory ganglia.
Clarification of the mechanisms by which CD81 T cells
block HSV-1 reactivation in latently infected sensory neu-
rons could provide new therapeutic approaches to prevent-
ing recurrent herpetic disease. The capacity to block reacti-
vation rather than simply treating an existing infection
would markedly reduce the human suffering, loss of pro-
ductivity, and visual impairment associated with HSV-1 in-
fections.
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